文献速递神经免疫

进展型起病多发性硬化患者中炎症与残疾累积的关联

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2018-01-01

基于MSBase国际数据库的观察性队列研究,纳入1419例进展型起病多发性硬化患者,分析叠加复发与确认残疾进展的关联。结果显示,有叠加复发者确认残疾进展风险较低(HR 0.83);疾病修饰治疗对确认残疾进展的保护作用仅在复发组中观察到,校正复发相关进展后该关联消失。

要点

  • 进展型起病多发性硬化中,叠加复发与确认残疾进展风险较低相关(HR 0.83)。
  • 疾病修饰治疗对确认残疾进展的保护作用仅在复发组中观察到。
  • 校正复发相关进展后,疾病修饰治疗与确认残疾进展的关联不再存在。

核心结论

  • 进展型起病多发性硬化中,叠加复发与确认残疾进展风险较低相关,可能归因于疾病修饰治疗预防复发相关残疾累积。
  • 作者认为炎症性复发是进展型起病疾病中残疾累积的重要且可干预的决定因素。

研究设计与样本

  • 观察性队列研究,数据来自MSBase前瞻性收集的国际数据库,收集时间为1995年1月至2017年2月,分析始于2017年2月。
  • 从44449例患者中识别出1419例(31.9%)符合条件者,纳入标准为原发进展型多发性硬化(PPMS)或进展复发型多发性硬化(PRMS)、成人起病、满足最低数据集要求(包括至少3次记录残疾的访视、第2次与最后1次访视间隔至少3个月)。
  • 采用多变量回归模型(Andersen-Gill)并纳入混合效应进行分析,另进行两项敏感性分析以排除复发相关残疾进展和 bouts 起病进展型多发性硬化。

主要发现

  • PRMS组患者较PPMS组年轻(平均[SD]年龄46[15]岁 vs 51[10]岁,Cohen d=0.40),入组时扩展残疾状态量表评分较低(平均[SD]评分4.0[3] vs 4.5[2.5],Cohen d=0.28)。
  • PRMS组与PPMS组男女比例相似(252:301 vs 394:472);总体平均[SD]年龄男性48(11)岁、女性50(10)岁。
  • 有叠加复发者确认残疾进展的可能性较低(HR 0.83;95% CI 0.74-0.94;P=.003)。
  • 在复发组中,随访时间中用于疾病修饰治疗的比例显著降低确认残疾进展风险(HR 0.96;95% CI 0.94-0.99;P=.01),而无复发组中无此关联(HR 1.02;95% CI 0.99-1.05;P=.26)。
  • 校正复发相关进展后,叠加复发组中疾病修饰治疗的关联不再存在(HR 1.10;95% CI 0.96-1.24;P=.16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) remains contested. OBJECTIVE: To examine the association of superimposed relapses in progressive-onset MS on disease outcomes. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study from MSBase, a prospectively collected, international database. Data were collected between January 1995 and February 2017. Analyses began in February 2017. From 44 449 patients at time of extraction, 1419 eligible patients (31.9%) were identified for analysis. Inclusion criteria consisted of primary progressive MS (PPMS) or progressive-relapsing MS (PRMS), adult-onset disease, and minimum data set (including ≥3 visits with disability recorded, ≥3 months between second and last visit). Data were analyzed using multivariable regression models (Andersen-Gill) with mixed effects. Two sensitivity analyses to exclude both relapse-related disability progression and bout-onset progressive MS were performed. EXPOSURES: Grouped according to presence or absence of relapse, defined as an acute episode of clinical worsening. Quantifiable disability change or correlation on imaging was not required to confirm relapse. MAIN OUTCOMES AND MEASURES: Cumulative hazard of disability progression. RESULTS: Patients with PRMS were younger than those with PPMS (mean [SD] age, 46 [15] vs 51 [10] years, Cohen d = 0.40) and demonstrated a mean lower Expanded Disability Status Scale score (mean [SD] score, 4.0 [3] vs 4.5 [2.5], Cohen d = 0.28) at inclusion. The ratio of men to women was similar in the PRMS and PPMS groups (252:301 vs 394:472). The overall mean (SD) age was 48 (11) years for men and 50 (10) years for women. Likelihood of confirmed disability progression was lower in patients with superimposed relapses (hazard ratio [HR], 0.83; 95% CI, 0.74-0.94; P = .003). Proportion of follow-up time spent on disease-modifying therapy significantly reduced the hazard of confirmed disability progression in the cohort with relapse (HR, 0.96; 95% CI, 0.94-0.99; P = .01) but not in those without relapse (HR, 1.02; 95% CI, 0.99-1.05; P = .26). When accounting for relapse-related progression, the association of disease-modifying therapy in the cohort with superimposed relapse was no longer observed (HR, 1.10; 95% CI, 0.96-1.24; P = .16). CONCLUSIONS AND RELEVANCE: In progressive-onset MS, superimposed relapses are associated with a lower risk of confirmed disability progression. This is most likely attributed to the association of disease-modifying therapy with the prevention of relapse-related disability accrual in patients with superimposed relapse. These findings suggest that inflammatory relapses are an important and modifiable determinant of disability accrual in progressive-onset disease.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hughes J, Jokubaitis V, Lugaresi A, et al. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurol. 2018. PMID: 30083762. doi:10.1001/jamaneurol.2018.2109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。